Novo Nordisk entered a deal to add long-acting peptide delivery capabilities to its cardiometabolic franchise, licensing Nanexa AB’s drug delivery technology under a global exclusive agreement. The package was valued at up to €1.165 billion (US$1.325 billion), according to the report. The Nanexa platform is positioned to extend dosing intervals for peptide therapies, aligning with Novo’s broader strategy to build more patient-friendly injection schedules across obesity and diabetes. The transaction also highlights how drug delivery is increasingly treated as a platform asset rather than a supporting technology. For biopharma development teams, the deal is a reminder that competitive advantage can shift from receptor biology into formulation and delivery timing—especially in cardiometabolic markets where adherence drives outcomes.